ACADIA Pharmaceuticals Inc. (ACAD) - What Are Brokerages Saying About This Stock?

Key Points

• Analyst sentiment is broadly positive: Eighteen firms give ACADIA a “Moderate Buy” consensus, with 13 Buy ratings and five Holds; the average 12-month price target is $31.55.
• Recent results topped expectations: Q3 revenue was $342.3 million and EPS was $0.31, beating consensus estimates, while revenue grew 22.8% year over year.
• Analysts have raised some price targets, with RBC citing continued momentum for Daybue; however, ACADIA also revised its 2026 earnings guidance, and the article does not specify the change.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) has earned an average rating of "Moderate Buy" from the eighteen ratings firms that are currently covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $31.55.

A number of analysts have recently commented on ACAD shares. Royal Bank Of Canada boosted their price target on ACADIA Pharmaceuticals from $36.00 to $38.00 and gave the company an "outperform" rating in a report on Thursday. BMO Capital Markets decreased their price objective on ACADIA Pharmaceuticals from $36.00 to $34.00 and set an "outperform" rating for the company in a report on Thursday, September 24th. Citizens Jmp decreased their price objective on ACADIA Pharmaceuticals from $36.00 to $33.00 and set a "market outperform" rating for the company in a report on Friday, September 25th. Bank of America reissued a "buy" rating and issued a $14.50 target price on shares of ACADIA Pharmaceuticals in a research report on Wednesday, July 29th. Finally, Weiss Ratings upgraded ACADIA Pharmaceuticals from a "hold (c)" rating to a "hold (c+)" rating in a research note on Wednesday, August 12th.

Key ACADIA Pharmaceuticals News

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: RBC raised its price target to $41 from $31 and maintained an Outperform rating, citing continued momentum for Daybue. RBC price-target update RBC Daybue commentary
• Positive Sentiment: Canaccord Genuity raised its target to $38 from $36 and reiterated a Buy rating, adding to the favorable analyst outlook. Canaccord analyst recommendations
• Positive Sentiment: ACADIA reported Q3 revenue of $342.3 million, above the roughly $332.6 million consensus, and earnings of $0.31 per share, ahead of estimates around $0.19–$0.20. Revenue increased 22.8% year over year, reinforcing the company’s growth story. Q3 earnings results
• Neutral Sentiment: The company revised its 2026 earnings guidance, but the provided report headline does not disclose the direction or magnitude of the change. Investors will need the detailed guidance to assess its implications. 2026 earnings guidance update

ACADIA Pharmaceuticals Trading Down 0.0%

ACAD opened at $21.23 on Friday. The stock has a market capitalization of $3.66 billion, a P/E ratio of 10.06 and a beta of 0.87. ACADIA Pharmaceuticals has a 12 month low of $18.39 and a 12 month high of $30.96. The firm's fifty day simple moving average is $22.86 and its 200 day simple moving average is $23.59.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last announced its earnings results on Wednesday, November 4th. The biopharmaceutical company reported $0.31 earnings per share for the quarter, topping analysts' consensus estimates of $0.20 by $0.11. The firm had revenue of $342.30 million during the quarter, compared to analyst estimates of $332.58 million. ACADIA Pharmaceuticals had a net margin of 30.13% and a return on equity of 8.90%. The company's revenue for the quarter was up 22.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.42 EPS. On average, equities research analysts predict that ACADIA Pharmaceuticals will post 0.74 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Mark Schneyer sold 3,321 shares of the firm's stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $20.88, for a total transaction of $69,342.48. Following the completion of the transaction, the executive vice president directly owned 71,322 shares of the company's stock, valued at $1,489,203.36. This trade represents a 4.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 26.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ACAD. Nykredit A S acquired a new stake in ACADIA Pharmaceuticals in the 2nd quarter valued at $38,000. Integrated Wealth Concepts LLC bought a new stake in ACADIA Pharmaceuticals during the 2nd quarter worth about $50,000. Global Retirement Partners LLC acquired a new position in shares of ACADIA Pharmaceuticals during the 2nd quarter worth about $64,000. GAMMA Investing LLC boosted its stake in shares of ACADIA Pharmaceuticals by 15.6% during the 2nd quarter. GAMMA Investing LLC now owns 2,985 shares of the biopharmaceutical company's stock worth $76,000 after buying an additional 402 shares during the last quarter. Finally, Sterling Capital Management LLC boosted its stake in shares of ACADIA Pharmaceuticals by 707.6% during the 3rd quarter. Sterling Capital Management LLC now owns 4,337 shares of the biopharmaceutical company's stock worth $87,000 after buying an additional 3,800 shares during the last quarter. Institutional investors and hedge funds own 96.71% of the company's stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system and neuropsychiatric disorders. The company's research programs target conditions with significant unmet medical needs, including neurological and rare neurodevelopmental diseases.

ACADIA's commercial products include NUPLAZID (pimavanserin), an atypical antipsychotic approved in the United States to treat hallucinations and delusions associated with Parkinson's disease psychosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.